Table 5 Multivariate logistic regression analysis for the risk for development of CIP/CIM and prolonged mechanical ventilation
Risk for development of CIP/CIMa | Risk for prolonged mechanical ventilationb | |||
|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | |
A. Uncorrected. | ||||
Glycaemic control, IIT | 0.33 (0.22 to 0.48) | < 0.0001 | 1.28 (0.86 to 1.89) | 0.2 |
B. Corrected for baseline risk factors. | ||||
Glycaemic control, IIT | 0.24 (0.14 to 0.42) | < 0.0001 | 0.56 (0.32 to 0.96) | 0.04 |
ICU type, medical | 0.49 (0.27 to 0.90) | 0.02 | 0.29 (0.16 to 0.53) | < 0.0001 |
Diagnostic category | ||||
Cardiovascular | 1.005 (0.55 to 1.82) | 0.9 | 0.78 (0.41 to 1.47) | 0.4 |
Cerebral/neurological | 0.77 (0.37 to 1.63) | 0.5 | 0.79 (0.36 to 1.72) | 0.5 |
Haematological/oncological/transplant | 1.04 (0.41 to 2.60) | 0.9 | 0.96 (0.35 to 2.63) | 0.9 |
Other | 1.02 (0.50 to 20.7) | 0.9 | 0.60 (0.29 to 1.26) | 0.2 |
Polytrauma | 1.03 (0.43 to 2.49) | 0.9 | 0.75 (0.29 to 1.90) | 0.5 |
Respiratory/thoracic | 1.43 (0.75 to 2.71) | 0.3 | 0.85 (0.44 to 1.64) | 0.6 |
On admission blood glucose | 0.99 (0.99 to 1.001) | 0.1 | 0.99 (0.99 to 1.002) | 0.7 |
Gender, female | 0.68 (0.47 to 1.000) | 0.05 | 0.63 (0.43 to 0.93) | 0.02 |
C. Corrected for baseline risk factors and known risk factors occurring during ICU stay. | ||||
Glycaemic control, IIT | 0.25 (0.14 to 0.43) | < 0.0001 | 0.40 (0.22 to 0.72) | 0.002 |
ICU type, medical | 0.62 (0.33 to 1.16) | 0.1 | 0.35 (0.18 to 0.67) | 0.002 |
Diagnostic category | ||||
Cardiovascular | 0.99 (0.54 to 1.83) | 0.9 | 0.64 (0.31 to 1.29) | 0.2 |
Cerebral/neurological | 0.83 (0.39 to 1.80) | 0.6 | 0.87 (0.36 to 2.11) | 0.8 |
Haematological/ | 1.18 (0.45 to 3.12) | 0.7 | 0.60 (0.19 to 1.93) | 0.4 |
oncological/transplant | 1.002 (0.49 to 2.07) | 0.9 | 0.58 (0.26 to 1.27) | 0.2 |
Other | 1.09 (0.43 to 2.73) | 0.9 | 0.88 (0.30 to 2.57) | 0.8 |
Polytrauma | 1.38 (0.72 to 2.66) | 0.3 | 089 (0.43 to 1.86) | 0.8 |
Respiratory/thoracic | ||||
On admission blood glucose | 0.99 (0.99 to 1.001) | 0.1 | 0.99 (0.99 to 1.002) | 0.4 |
Gender, female | 0.74 (0.50 to 1.09) | 0.1 | 0.74 (0.48 to 1.12) | 0.2 |
Number of days treatment with noradrenaline, per day added | 1.002 (0.98 to 1.03) | 0.8 | 1.16 (1.11 to 1.22) | < 0.0001 |
Cumulative dose hydrocortisone equivalent, per mg added | 1.000 (1.000 to 1.000) | 0.3 | 1.00 (1.00 to 1.00) | 0.9 |
Treatment with aminoglycosides, yes | 1.073 (0.69 to 1.68) | 0.8 | 1.72 (1.003 to 2.96) | 0.05 |
Number of days treatment with NMBAs (min 1 bolus or drip), per day added | 1.04 (0.98 to 1.10) | 0.2 | 1.15 (1.04 to 1.27) | 0.007 |
Number of days treatment with dialysis, per day added | 1.004 (0.98 to 1.02) | 0.7 | 1.09 (1.03 to 1.15) | 0.004 |
Time t, per day added | 1.01 (0.99 to 1.03) | 0.2 | - | - |
Bacteraemia, yes | - | - | 2.11 (1.26 to 3.55) | 0.005 |